Mabwell(SSE:688062)isaninnovation-drivenbiopharmaceuticalcompanywithanentireindustrychainofR&D,manufacturing,andcommercialization.Consistentwithourcommitmenttoprovidemoreeffectiveandaccessibletherapiesandinnovativeproducts,Mabwellhasworkedtofulfillglobalmedicalneedsandbringlife-changingsolutionstopatients.
MabwellAnnouncesStrategicPartnershipwithTABUKtoLaunchBiosimilarsintheMENARegion
MabwellInksLicensingandCommercializationAgreementofDenosumabInjectionforPeruvianMarket
Mabwell'sNovelNectin-4TargetingADC9MW2821Approvedfor2ClinicalTrialsbyCDEofNMPA
MabwellRevealsEncouragingPre-clinicalDataof7MW4811atthe15thWorldADCConference
MabwellAnnouncesCDEApprovaltoInitiatePhaseIIIClinicalTrialof9MW2821forUrothelialCarcinomainCombinationwithPD-1Inhibitor
MabwellAnnouncestheCDEApprovalofNovelNectin-4TargetingADCtoInitiatePhaseIIIClinicalTrialfortheTreatmentofCervicalCancer